Pregnant women suffering from severe morning sickness – known as Hyperemesis Gravidarum (HG) – have been speaking out about the barriers they face in accessing a highly effective medication through the NHS.
Jasmeen Basi, a mother of three from Southampton, experienced debilitating sickness during her pregnancies. Desperate for relief, she requested Xonvea (Doxylamine Succinate and Pyridoxine Hydrochloride), which had shown promise in clinical trials. However, she encountered 'red tape', requiring daily calls to chase the prescription – a frustrating experience that ultimately led her to seek private healthcare.
A survey conducted by Pregnancy Sickness Support last year found that nearly all women who tried Xonvea reported it was effective, often surpassing other treatments they had used. This is testament to its potential benefit for those experiencing HG.
According to NHS guidelines, the use of Xonvea for HG management is supported by evidence from a leading developer, Professor Catherine Nelson-Piercy. While it holds an 'equal place' as a safe and effective treatment alongside other options, local healthcare policies can impact access – with prices varying between £28 per packet and just £3-£4 for older antihistamines.
Hyperemesis Gravidarum affects approximately 1-3% of pregnant women, leading to significant weight loss, dehydration, and nutritional deficiencies. If not managed effectively, it can require hospitalisation. The inconsistent access to treatments like Xonvea can have far-reaching consequences for those affected.